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Abstract:  
 
Two new cyclodepsipeptides (1 and 2), two new sesquiterpenoids (3 and 4), and the known 
compounds guangomide A (5), roseotoxin S, and three simple trichothecenes were isolated from 
the cytotoxic organic extract of a terrestrial filamentous fungus, Trichothecium sp. The structures 
were determined using NMR spectroscopy and mass spectrometry. Absolute configurations of 
the cyclodepsipeptides were established by employing chiral HPLC, while the relative 
configurations of 3 and 4 were determined via NOESY data. The isolation of guangomide A was 
of particular interest, since it was reported previously from a marine-derived fungus. 
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Article:  
 
Through our ongoing investigation of diverse organisms for anticancer drug leads,(1, 2) an 
extract of the fungus Trichothecium sp., from the Mycosynthetix library of filamentous fungi, 
displayed promising cytotoxicity, with less than 20% survival of human tumor cells when treated 
with 20 μg/mL of crude extract. Subsequent bioactivity-directed fractionation studies led to the 
isolation and characterization of nine secondary metabolites, four of which were new. The 
isolates could be subclassified as four depsipeptides (compounds 1 and 2 being new) and five 
sesquiterpenoids (compounds 3 and 4 being new). Furthermore, one of the known 
cyclodepsipeptides was guangomide A (5), which was described previously from an unidentified 
marine-derived, rather than in this case a terrestrial, fungus.(3) Species of the 
genusTrichothecium have been a rich source of secondary metabolites.(4) As just one example, 
at least 29 secondary metabolites have been described from T. roseum,(4-12) ranging from 
depsipeptides such as the destruxins, roseotoxins, and roseocardin, to terpenoids such as 
eremophilanes, rosenoic acids, and trichothecenes, indicative of the vast biosynthetic potential of 
this, and perhaps related, fungi. 
 
 
 
Chart 1 
 
Compound 1 was assigned the molecular formula C36H56N4O9 via HRESIMS data (m/z711.3923 
for [M + Na]+), establishing an index of hydrogen deficiency (IHD) of 11. The 1H and13C NMR 
spectra suggested that 1 was a depsipeptide-type compound on the basis of chemical shifts and 
multiplicities typical for α protons and carbons (Table 1). In general, cyclodepsipeptides are 
secondary metabolites that contain amino acids and at least one hydroxy acid linked through 
ester and amide bonds to form a cyclic structure. 1H NMR data (Table 1) revealed the presence 
of five aromatic protons (δH 7.19–7.26 for H-5 to H-9), suggesting a phenylalanine (Phe) residue. 
Six α protons were also evident (δH 5.45, 5.29, 4.73, 4.65, 4.52, and 3.45 for H-11, H-2, H-22, H-
17, H-25, and H-31, respectively). Moreover, three NH protons (δH 7.93, 7.46, and 5.92) and an 
N-methyl group (δH 3.06) were observed, as were signals evident of an O–CH2 moiety (δH 4.21 
and 4.05, H2-23). Most other resonances were found in the upfield region of the 1H NMR 
spectrum, including those for both methylene and methine protons (δH 2.98, 2.84, 1.95, 1.34, and 
a multiplet from 1.71 to 1.53) and eight doublet methyl resonances (δH 0.91, 0.90, 1.02, 1.01, 
0.87, 0.93, 0.81, and 0.78, for H3-14, H3-15, H3-19, H3-20, H3-28, H3-29, H3-34, and H3-35, 
respectively). HSQC data further confirmed the presence of five CH2 resonances (H2-3, H2-12, 
H2-26, H2-32), including an oxymethylene (H2-23), and eight methyl groups. Data from the 13C 
and DEPT-135 NMR spectra indicated 36 carbon resonances, consistent with the molecular 
formula, including six ester and/or amide carbonyl carbons (δC172.4, 171.9, 170.5, 170.2, 169.7, 
and 167.8, for C-1, C-24, C-30, C-21, C-10, and C-16, respectively), six aromatic carbons 
(δC 135.8, 129.4 × 2, 128.5 × 2, and 127.1, for positions C-4 to C-9), three oxygenated carbons 
(δC 79.0, 73.5, and 63.4, for C-17, C-11, and C-23, respectively), and four nitrogen-bearing 
carbons (δC 65.1, 54.9, 51.7, and 50.1, for C-31, C-22, C-25, and C-2, respectively). COSY data 
(Figure 1) were key in the establishment of spin systems, leading to the identification of the 
hydroxy and amino acid residues. Some of the prominent spin systems include a Phe moiety 
(from NH at δ 7.46 to H-2 and H-3 and from H-5 to H-9), a hydroxyisocaproic acid (Hic) moiety 
(from H-11 to H3-15), a hydroxyisovaleric acid (Hiv) moiety (from H-17 to H3-20), a serine 
(Ser) moiety (from NH at δ 7.93 to H-22 and H-23), a leucine (Leu) moiety (from NH at δ 5.92 
to H-25 through H3-29), and a second leucine (Leu) moiety (from H-31 to H-35). The lack of 
COSY correlations from any NH signal to the α proton of the latter Leu system suggested an 
NMe group, which was supported by the upfield chemical shift of this proton (δH 3.45; H-
31);(3) indeed, an HMBC correlation from an NMe group (H3-36) to C-31 confirmed this 
assignment. HMBC correlations from H2-3 to the aromatic carbons C-4, C-5, and C-9 revealed 
the presence of Phe, while correlations from each α proton and NH proton to each carbonyl 
carbon helped establish the connectivities in the core of the structure (Figure 1). HMBC 
correlations from H-2 to C-1, C-3, and C-10, from the NH proton at δ 7.46 to C-10 and C-2, and 
from H-11 to C-10 suggested that Hic acylates Phe; correlations from H-11, H-17, and H-18 to 
C-16 suggested that Hiv acylates Hic; correlations from H-17, H-22, and H-23 to C-21 suggested 
that Ser acylates Hiv; correlations from the NH proton at δ 7.93 and H-25 to C-24 suggested that 
Leu acylates Ser; correlations from the NH proton at δ 5.92 and H-31 to C-30 suggested that 
NMeLeu acylates Leu; and correlations from H2-3 and H3-36 to C-1 suggested that Phe acylates 
the NMeLeu. These connectivities confirmed the cyclic hexadepsipeptide nature of compound 1, 
thereby satisfying the IHD. 
 
 
 
Table 1. NMR Data for Compounds 1 and 2a 
 
Compound 2 was assigned the molecular formula C35H54N4O9 on the basis of HRESIMS data 
(m/z 697.3770 for [M + Na]+), establishing an IHD of 11. It had a spectroscopic profile similar 
to1, but differences were apparent in the 13C and DEPT-135 NMR data, where 2 displayed one 
less methylene than 1. This finding was supported by the HRESIMS data of 2, which were 14 
amu less than 1. Further analyses of the 2D NMR data revealed that 2 contained the amino acid 
valine (Val), instead of the Leu unit present in 1, which acylates Ser. This was apparent from the 
signals for the isopropyl unit (H-27 to H-29) connected to the α carbon at C-25, as observed via 
HMBC and COSY correlations. 
 
 
 
Figure 1. Selected HMBC (→) and COSY (—) correlations for 1. 
 
The absolute configurations of the α carbons of compounds 1 and 2 were determined via chiral 
HPLC analyses performed on the hydrolysis products.(13-15) For the organic extracts of the acid 
hydrolysates, comparison of retention times with those of standard hydroxy acids revealed the 
Hiv and Hic units of 1 and 2 to both be of the L-configuration. All four amino acids were 
determined to be of the L-configuration in both 1 and 2 by a similar analysis of the aqueous 
extracts of the acid hydrolysates. The closest known compound to these new cyclodepsipeptides 
was hirsutatin A, which was isolated from the pathogenic fungus Hirsutella nivea.(13) However, 
hirsutatin A differs due to a L-threonine unit instead of L-Leu (1) or L-Val (2) units. The new 
isolates were ascribed the trivial names trichodepsipeptide A (1) and trichodepsipeptide B (2) 
due to their isolation from Trichothecium sp. 
 
Compound 3 was ascribed a molecular formula of C22H32O8 on the basis of HRESIMS data 
(m/z447.1981 for [M + Na]+), indicating an IHD of 7. The 1H NMR data (see Experimental 
Section) showed the presence of five olefinic protons (δH 6.47, 6.11, 5.85, 5.28, and 5.06 for H-
5′, H-4′, H-6′, H-2′, and H-10′, respectively), four oxygenated methine protons (δH 5.23, 5.19, 
4.63, and 3.82 for H-1, H-1′, H-5, and H-4, respectively), one methoxy group (δH 3.74, H-7), 
four methylene protons (δH 2.08 for H2-8′ and H2-9′), and four vinyl methyl groups (δH 1.92, 
1.77, 1.66, and 1.58 for CH3-3′, CH3-7′, CH3-13′, and CH3-12′, respectively). The 13C and DEPT-
135 data revealed 22 carbons, consistent with the molecular formula and indicative of two 
carbonyl carbons, likely a ketone and an ester (δC 193.6 and 170.8, for C-2 and C-6, 
respectively), eight olefinic carbons (δC 140.6, 140.1, 134.2, 132.0, 126.4, 125.7, 125.1, and 
124.0 for C-7′, C-3′, C-4′, C-11′, C-5′, C-2′, C-6′, and C-10′, respectively), six oxygenated 
carbons, including that of a methoxy signal (δC 99.3, 61.5, 64.4, 65.9, 56.8, and 56.1 for C-1, C-
3, C-1′, C-5, C-7, and C-4, respectively), two methylenes (δC 40.3 and 26.8 for C-8′ and C-9′, 
respectively), and four vinylic methyl groups (25.9, 17.9, 17.1, and 13.6 for C-13′, C-12′, CH3-7′, 
and CH3-3′, respectively). COSY data (Figure 2) identified four spin systems, for example, those 
from H2-8′ to H-10′, from H-4′ to H-6′, from H-1′ to H-2′, and from H-4 to H-5; the J value of 15 
Hz for coupling between H-4′ and H-5′ verified a trans double bond. A sesquiterpenoid side 
chain was apparent from HMBC correlations from H-1′ to H-13′ (Figure 2). The point of 
attachment for the side chain was evident from HMBC correlations from H-2′ to C-3 and from 
H-1′ to C-2, C-4, and C-3, suggesting that the quaternary carbon C-3 was connected directly to 
C-1′ and flanked by the ketone carbonyl C-2 and the oxygenated C-4. HMBC correlations from 
H-1 to C-2, C-3, and C-5 and from H-5 to C-1 suggested that the anomeric proton (H-1) was 
connected to C-2 and C-5; the latter was via an ether linkage, thereby satisfying the oxygen 
atoms required by the molecular formula. Finally, correlations from H-4 to C-3, C-5, and C-6, 
from H-5 to C-6, and from H3-7 to C-6 established the six-membered ring with the 
carboxymethyl group attached at C-5. The sesquiterpenoid chain (C-1′ to C-12′) with a 
conjugated triene was similar to the oligosporon group of compounds, which were isolated from 
the nematode-trapping fungus Arthrobotrys oligospora.(16) However, compound 3 had a unique 
ring portion that was derived from a sugar unit (hexanose). Compound 3 was ascribed the trivial 
name trichothosporon A. 
 
The relative configuration of 3 was determined via a NOESY experiment. This revealed that H-5 
and H-4 were on the same face of the ring. Moreover, a correlation between H-1 and the 
methoxy moiety of the ester showed these were on the opposite face. Unfortunately, it was not 
possible to determine the relative configuration at H-1′ unambiguously through the same 
experiment. Several unsuccessful reactions were attempted, resulting in decomposition of 
compound 3. Thus, the absolute configuration remains undetermined at this time. 
 
 
Figure 2. Selected HMBC (→) and COSY (—) correlations for 3. 
 
Compound 4 (C19H26O6 by HRMS) was a new trichothecene analogue, which was related in 
structure to a previously reported (and unnamed) synthetic intermediate.(17) On the basis of 
NMR data, compound 4 retained the core of the trichothecene structure, but key signals for the 
epoxide moiety were replaced by a methylene unit (H2-13). The geminal coupling constant of 
these protons (J = 12 Hz) was too large for an epoxide moiety (typically 4 Hz), suggesting a 
larger ring system. HMBC data indicated the presence of either a tetrahydropyran ring 
(connecting C-7 to C-13 and the formation of a tertiary alcohol at C-12) or a tetrahydrofuran ring 
(connecting C-7 to C-12 with a free CH2OH at C-13). Chemical shifts of the methylene group at 
C-13 were consistent with the former.(17) Furthermore, acetylation with pyridine–acetic 
anhydride resulted in the incorporation of only one acetyl group, indicating that 4 had only one 
OH group susceptible to the reaction (i.e., position 8). NOESY data showed correlations between 
H-11 and H2-13, which suggested that these protons were on the same face of the molecule, 
while the broad singlet signals for H-7 and H-8, together with their NOESY correlations, 
suggested that H-7 and H-8 were on the opposite face of the molecule from H-11. 
 
Five other known compounds, guangomide A (5),(3) roseotoxin S,(18) crotocin,(17, 
19)trichothecinol B,(20) and trichothecin,(4, 19) were isolated and elucidated; in all cases, the 
structural data were in agreement with the literature. The identification of the 
cyclodepsipeptide5 was of particular interest, as it was described initially from an unidentified 
fungal strain isolated from an Ianthella sponge.(3) The NMR data of 5 were identical to the 
literature (see Supporting Information), although comparison of the optical rotation showed 
opposite signs (literature: −44.6 vs compound 5: +6.5). Crystals of 5 suitable for X-ray 
crystallographic analysis were generated, which were identical to the literature as well (data not 
shown). This could mean that5 was either guangomide A or its enantiomer. Amino acid analysis 
and Marfey’s derivatization of the acid hydrolysis products of 5 showed the same amino acid 
residues as reported for guangomide A, particularly L-NMeAla and D-NMePhe (see Supporting 
Information for UPLC chromatograms of the amino acid analyses). Thus, compound 5 was 
presumed to be guangomide A;(3) the difference in optical rotation values cannot be explained at 
this time. To the best of our knowledge, this is the first description of 5 from a terrestrial 
organism. Crews and colleagues reported weak antibacterial activity for 5 vs Staphylococcus 
epidermidis andEnterococcus durans (MIC values of 100 μg/mL in both assays).(3) The same 
authors reported5 as inactive against murine and human tumor cell lines in a disk diffusion assay. 
In the human tumor panel, 5 displayed EC50 values of approximately 15 μM against MCF-7, 
H460, and SF268 cell lines. 
 
The new compounds (1–4) were not active in the human tumor panel (i.e., IC50 values > 10 μM 
against all cell lines). Thus, roseotoxin S and the trichothecene analogues likely account for the 
cytotoxicity observed with the crude extract. Our team reported recently a procedure to 
dereplicate macrocyclic trichothecenes,(21) and studies are ongoing to augment those methods 
for simple trichothecenes. Regardless, the biosynthetic potential of this fungus was quite 
intriguing, given the variety of structural types isolated on a nonoptimized culture that was 
collected over two decades ago. 
 
EXPERIMENTAL SECTION 
 
General Experiment Procedures 
UV spectra and optical rotations were acquired on a Varian Cary 100 Bio UV–vis 
spectrophotometer and a Rudolph Research Autopol III polarimeter, respectively. NMR spectra 
were recorded on a JEOL ECA-500, operating at 500 MHz for 1H and 125 MHz for 13C. HPLC 
was carried out using a Varian Prostar HPLC system equipped with ProStar 210 pumps and a 
Prostar 335 photodiode array detector, with data collected and analyzed using Galaxie 
Chromatography Workstation software (version 1.9.3.2). For preparative HPLC, a YMC ODS-A 
(5 μm; 250 × 20 mm) column was used with a 10 mL/min flow rate; for the semipreparative 
HPLC, a YMC ODS-A (5 μm; 250 × 10 mm) column was used with a 5 mL/min flow rate; for 
analytical HPLC, YMC ODS-A (5 μm; 150 × 4.6 mm) columns were used with a 1 mL/min flow 
rate (all from Waters). For analytical HPLC, MetaTherm HPLC column temperature controllers 
(Varian) maintained these columns at 30 °C. Reversed-phase chiral HPLC was carried out using 
a Chirex 3126 D-penicillamine (5 μm; 150 × 4.6 mm) column at 1 mL/min flow rate 
(Phenomenex). UPLC was carried out on a Waters Acquity UPLC system (Waters; Milford, MA, 
USA) using a Waters HSS T3 C18 column (1.8 μm; 2.1 × 100 mm) maintained at 40 °C. 
HRESIMS on compounds 1–3 were performed by direct injection coupled to QtofMS using a 
Waters SYNAPT MS system; HRMALDITOFMS data for compounds 4 and 5 were acquired 
with an Applied Biosystems TOF/TOF mass spectrometer using conditions described 
previously.(22)Flash chromatography was conducted using a CombiFlash Rf system using 
RediSep Rf Si gel columns (both from Teledyne-Isco). 
 
Producing Organism and Fermentation 
Mycosynthetix fungal strain 51320 was isolated by Dr. Barry Katz of MYCOsearch in 
September 1990 from leaf litter collected in Leon County, approximately 2 miles east southeast 
of Tallahassee, FL, USA. DNA analyses were performed by MIDI Laboratories, Inc. (Newark, 
DE, USA), and the D2 variable region of the large subunit (LSU) rRNA was sequenced and 
compared to their database. This analysis suggested that this fungus was related 
toTrichothecium sp. (order Hypocreales); these data were deposited in Genbank (accession 
no.JF930284). The culture was stored on a malt extract slant and was transferred periodically. A 
fresh culture was grown on a similar slant, and a piece was transferred to a medium containing 
2% soy peptone, 2% dextrose, and 1% yeast extract (YESD media). Following incubation (7 d) 
at 22 °C with agitation, the culture was used to inoculate 50 mL of a rice medium, prepared 
using rice to which was added a vitamin solution and twice the volume of rice with H2O, in a 250 
mL Erlenmeyer flask. This was incubated at 22 °C until the culture showed good growth 
(approximately 14 d). The scale-up culture was grown in a 2.8 L Fernbach flask containing 150 g 
of rice and 300 mL of H2O and was inoculated using a seed culture grown in YESD medium. 
This was incubated at 22 °C for 14 d. 
 
Extraction and Isolation 
To the large-scale solid fermentation was added 500 mL of 1:1 MeOH–CHCl3. The mixture was 
shaken for 24 h, then filtered, and the solvent was evaporated (waxy yellow solid). This crude 
extract was partitioned between CHCl3–MeOH–H2O (4:1:5), and the organic soluble material 
was dried and further partitioned between hexanes and CH3CN (1:1). The CH3CN partition (4 g) 
was fractionated via flash chromatography using silica gel via a hexanes–CHCl3–MeOH gradient 
to afford four fractions. Fraction 2 (1.5 g), which eluted with 0 to 10% MeOH in CHCl3 over 14 
min, was separated further by reversed-phase HPLC (20–100% CH3CN–H2O over 100 min) to 
obtain 18 fractions. Fraction 13 yielded guangomide A (4; 91 mg). Fraction 14 (11.4 mg) was 
purified by semipreparative reversed-phase HPLC (20–100% CH3CN–H2O over 15 min) to yield 
trichothosporon A (3, 3 mg). Fraction 16 (9.4 mg) was separated further by semipreparative 
reversed-phase HPLC (20–100% CH3CN–H2O over 15 min) to obtain trichodepsipeptide B (2; 4 
mg), while similar separation conditions were utilized on fraction 17 (18 mg) to yield 
trichodepsipeptide A (1; 7 mg). An initial sample of this same fungus was processed in the same 
fashion to yield a CH3CN partition (672 mg), which was subjected to flash chromatography 
using silica gel via a hexanes–CHCl3–MeOH gradient to afford seven fractions. Fraction 5 (490 
mg) was separated further by preparative reversed-phase HPLC (20–100% CH3CN–H2O over 
100 min) to yield a new trichothecene analogue (4; 17 mg), trichothecin (6 mg), crotocin (7 mg), 
a mixture of roseotoxin S and trichothecinol B (16 mg), guangomide A (5; 22 mg), and 
trichothosporon A (3; 22 mg). 
 
Trichodepsipeptide A (1): 
white powder; [α]25D −45.6 (c 0.3, CHCl3); UV (MeOH) λmax (log ε) 206 (2.97); 1H, 13C NMR, 
and HMBC data, see Table 1; HRESIMS m/z 711.3923 [M + Na]+ calcd for C36H56N4O9Na, 
711.3945. 
 
Trichodepsipeptide B (2): 
white powder; [α]25D −79.0 (c 0.1, CHCl3); UV (MeOH) λmax (log ε) 203 (2.67); 1H, 13C NMR 
and HMBC data, see Table 1; HRESIMS m/z 697.3770 [M + Na]+, calcd for C35H54N4O9Na, 
697.3788. 
 
Trichothosporon A (3): 
white powder; [α]25D −8.8 (c 0.1, CHCl3); 1H NMR (500 MHz, CDCl3) δ 5.23 (s, H-1), 3.82 
(d, J = 3, H-4), 4.63 (d, J = 3, H-5), 3.74 (s, H-7), 5.19 (d, J = 9, H-1′), 5.28 (d, J = 9, H-2′), 6.11 
(d, J = 15, H-4′), 6.47 (dd, J = 15, 11, H-5′), 5.85 (d, J = 11, H-6′), 2.08 (m, H-8′), 2.08 (m, H-
9′), 5.06 (m, H-10′), 1.58 (s, H-12′), 1.66 (s, H-13′), 1.92 (d, J = 1, 3′-CH3), 1.77 (s, 7′-CH3); 13C 
NMR (125 MHz, CDCl3) δ 99.3 (C-1), 193.6 (C-2), 61.5 (C-3), 56.1 (C-4), 65.9 (C-5), 170.8 (C-
6), 56.8 (C-7), 64.4 (C-1′), 125.7 (C-2′), 140.1 (C-3′), 134.2 (C-4′), 126.4 (C-5′), 125.1 (C-6′), 
140.6 (C-7′), 40.3 (C-8′), 26.8 (C-9′), 124.0 (C-10′), 132.0 (C-11′), 17.9 (C-12′), 25.9 (C-13′), 
13.6 (3′-CH3), 17.1 (7′-CH3); HRESIMS m/z 447.1981 [M + Na]+, calcd for C22H32O8Na, 
447.1995. 
 
Trichothecene analogue (4): 
colorless film; [α]25D −11.0 (c 0.1, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.35 (dq, J = 11.5, 7.5, 
H-3′), 5.77 (dq, J = 11.5, 2, H-2′), 5.58 (d, J = 6, H-10), 5.51 (dd, J = 8, 3.4, H-4), 4.20 (d, J = 5, 
H-2), 3.95 (br s., H-8), 3.92 (d, J = 12, Ha-13), 3.83 (br s., H-7), 3.63 (d, J = 7, H-11), 3.61 
(d, J= 12, Hb-13), 2.39 (dd, J = 15.5, 8.6, Ha-3), 2.12 (m, Hb-3), 2.11 (dd, J = 7.5, 2, H-4′), 1.84 
(s, H3-16), 1.03 (s, H3-15), 0.92 (s, H3-14); 13C NMR (125 MHz, CDCl3) δ 165.9 (C-1′), 146.7 
(C-3′), 136.8 (C-9), 121.4 (C-10), 120.2 (C-2′), 82.6 (C-2), 77.0 (C-7), 74.8 C-4), 74.6 (C-12), 
72.5 (C-8), 69.7 (C-11), 66.7 (C-13), 50.1 (C-5), 38.9 (C-6), 37.3 (C-3), 20.7 (C-16), 15.8 (C-
15), 15.7 (C-4′), 6.7 (C-14); HMBC data, H-2 → C-5, C-11, C-12; H2-3 → C-2, C-4; H-4 → C-
1′, C-2, C-5, C-6, C-12; H-7 → C-5, C-8, C-7; H-8 → C-6, C-7, C-9, C-10, C-16; H-10 → C-6, 
C-8, C-11, C-16; H-11 → C-2, C-9, C-10; H2-13 → C-2, C-5, C-12; H3-14 → C-4, C-5, C-6; H3-
15 → C-5, C-6; H3-16 → C-8, C-9, C-10; H-2′ → C-1′, C-4′; H-3′ → C-1′, C-4′; H3-4′ → C-1′, 
C-2′; HRESIMS m/z373.1620 [M + Na]+, calcd for C19H26O6Na, 373.1622. 
 
 
 
Guangomide A (5): 
[α]25D +6.5 (c 0.31, CHCl3); 1H and 13C NMR data matched the 
literature;(3) HRMALDITOFMSm/z 641.3163 [M + Na]+, calcd for C31H46N4O9Na, 641.3157. 
 
Amino Acid Analysis by Chiral HPLC.(13-15) 
Independently, an aliquot of compounds 1 (2 mg) and 2 (2 mg) were subjected to hydrolysis with 
6 N HCl (1 mL) in a sealed tube at 100 °C for 24 h. Upon cooling, the solutions were evaporated 
to dryness. Each residue was dissolved in H2O and extracted with diethyl ether (2 × 2 mL). Both 
organic and aqueous solutions were subjected to chiral HPLC analysis at a flow rate of 1.0 
mL/min using four different solvent systems: (1) 5% 2-propanol in 2 mM CuSO4: L-Hiv (tR = 15 
min), D-Hiv (tR = 27 min), L-Hic (tR = 49 min), D-Hic (tR = 68 min), L-NMeLeu (tR = 12 min), D-
NMeLeu (tR = 17 min); (2) 5% MeOH in 2 mM CuSO4: L-Ser (tR = 4.9 min), D-Ser (tR = 5.3 
min); (3) 30% MeOH in 2 mM CuSO4: L-Phe (tR = 25 min), D-Phe (tR = 35 min), L-Leu (tR = 15 
min), D-Leu (tR = 18 min); (4) 100% 1 mM CuSO4: L-Val (tR = 26 min), D-Val (tR = 47 min). 
Dilutions were adjusted in each case to approximate the response of the UV detector (λ = 214 
nm) with those of hydrolyzed samples. 
 
Amino Acid Analysis of Marfey’s Derivatives(23) by UPLC 
A sample of compound 5 (2.3 mg) was subjected to acid hydrolysis in a manner similar to the 
above. The dried aqueous solution was resuspended in H2O (100 μL), and 1% Marfey’s reagent 
in acetone (200 μL) and 1 M NaHCO3 (40 μL) were added. The mixture was heated at 40 °C for 
1 h in a shaking water bath, after which it was removed and cooled. The mixture was quenched 
with 2 M HCl (20 μL), dried, and dissolved in MeOH for UPLC analysis. Amino acid standards 
(1 mg each) were derivatized with Marfey’s reagent in a manner similar to the above. The UPLC 
analysis was performed using two solvent systems: (1) 10–50% CH3CN–0.1% TFA in H2O over 
10 min at a flow rate of 0.5 mL/min: L-NMePhe (tR = 8.334 min), D-NMePhe (tR = 8.447 
min), L-Ala (tR = 5.281 min), D-Ala (tR = 6.186 min); (2) 10–70% MeOH–0.1% TFA in H2O 
over 10 min at a flow rate of 0.4 mL/min: L-NMeAla (tR = 7.730 min), D-NMeAla (tR = 7.682 
min), L-Ala (tR = 6.836 min), D-Ala (tR = 8.067 min). 
 
Cytotoxicity Assay 
The cytotoxicity measurements against MCF-7(24) human breast carcinoma (Barbara A. 
Karmanos Cancer Center, Detroit, MI, USA), NCI-H460(25) human large-cell lung carcinoma 
(HTB-177, American Type Culture Collection, Manassas, VA, USA), and SF-268(26) human 
astrocytoma (NCI Developmental Therapeutics Program, Frederick, MD, USA) cell lines were 
performed as described previously.(22) Compounds 1 and 2 were also tested against the HT-
29(27) human colorectal adenocarcinoma (HTB-38, American Type Culture Collection) and 
MDA-MB-435(28) human melanoma (HTB-129, American Type Culture Collection) cell lines 
as described previously.(29) 
 
Supporting Information 
1H and 13C NMR spectra of compounds 1–4. These materials are available free of charge via the 
Internet at http://pubs.acs.org. 
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